Novo Nordisk filed suit against Hims & Hers for patent infringement on semaglutide, the active ingredient in Wegovy and Ozempic.[1][2] Novo Nordisk General Counsel John Kuckelman told STAT that telehealth companies and compounding pharmacies that continue to manufacture knockoff versions of Wego should be "very, very vigilant".[1] Compounding pharmacies began making copies of GLP-1 drugs when the originals were in short supply, which was legally allowed, but after the shortage ended last year, companies like Hims continued to sell "personalized" versions.[1] The lawsuit also involves oral semaglutide, which Hims had only recently announced but withdrew following a recommendation from the HHS general counsel to the Department of Justice.[3] Novo alleges that Hims is selling illegal bulk compounded injectable versions with inauthentic ingredients, putting patients' health at risk.[2] Novo tests found up to 86% impurities in compounded injectable semaglutides, which can lead to anaphylactic shock.[3] The firm is seeking hundreds of millions of dollars in damages, including a three-fold increase.[2]